1 The EIC Accelerator Project
EIC Accelerator Program Overview
The European Innovation Council (EIC) Accelerator program serves as a pivotal funding mechanism aimed at supporting innovative startups and small to medium-sized enterprises (SMEs) within the European Union. Established under the Horizon Europe framework, the program is designed to catalyze the growth of deep tech and high-impact innovations that can lead to significant societal and economic advancements.
Funding Structure
The EIC Accelerator provides a unique blend of financial support comprising both grants and equity investments.
Purpose and Impact of the EIC Accelerator
The EIC Accelerator plays a crucial role in the European startup ecosystem, particularly in the deep tech sector. Its primary objectives include:
- Fostering Innovation: The program provides essential funding that allows innovative companies to develop breakthrough technologies and solutions.
- Scaling Up: By offering substantial financial resources, the EIC Accelerator assists companies in scaling their operations, moving from the development phase to market entry and expansion.
- Attracting Private Investment: The equity component is specifically designed to leverage additional funding from private investors. By demonstrating credibility and reducing risk through early-stage funding, the EIC Accelerator enhances a company’s appeal to venture capitalists and other financing sources.
BETAGLUE TECHNOLOGIES S.P.A. and the BAT-90 Project
Company Overview: BETAGLUE TECHNOLOGIES S.P.A., based in Italy, is a pioneering company focused on developing innovative medical solutions. The company recently gained recognition through its successful application in the EIC Accelerator program.
Project Acronym: BAT-90
Project Title: A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours
Funding Type: Blended Finance
Submission Date: November 8, 2023
Project Description: The BAT-90 project introduces a cutting-edge platform technology aimed at revolutionizing the treatment of solid tumors. The core concept of BAT-90 is the development of a novel radiotherapy method that administers radiation directly within the tumor site, thereby enhancing treatment efficacy while minimizing damage to surrounding healthy tissues.
Technology Basics and Background
Radiotherapy from Within: Traditional radiotherapy techniques often involve the external application of radiation, which can lead to collateral damage to healthy cells and tissues. BAT-90 proposes a paradigm shift by utilizing a localized approach that targets tumors internally. This method enhances the precision and effectiveness of the treatment, potentially leading to improved patient outcomes and reduced side effects.
Platform Technology: The platform enables the integration of advanced materials and innovative delivery mechanisms to ensure that radiation is accurately administered to the tumor site. This technology is particularly relevant in treating various types of solid tumors, which can be notoriously challenging due to their complex biological environments.
Market Potential: With rising incidences of cancer globally, the demand for effective treatment modalities is ever-increasing. BAT-90 positions BETAGLUE TECHNOLOGIES at the forefront of a rapidly evolving medical landscape, making significant contributions to oncology and patient care.
In conclusion, the EIC Accelerator program not only provides vital financial support to innovative companies like BETAGLUE TECHNOLOGIES S.P.A. but also plays a strategic role in nurturing the European deep tech ecosystem. By enabling projects like BAT-90, the EIC Accelerator is fostering advancements that have the potential to transform healthcare and improve the lives of patients battling solid tumors.
2 The Funding Rounds
Financing Raised Since EIC Accelerator Award
Following its successful application for the EIC Accelerator funding in November 2023, BetaGlue Technologies S.p.A., an Italian clinical-stage radiotherapy company, has completed a series of significant financing rounds to support the development of its novel cancer therapies.
Key Funding Rounds and Timing
- EIC Accelerator Award (March 2024):
- Total: €10 million
- Structure: €2.5 million grant + €7.5 million equity (“blended finance”)
- Purpose: Advance clinical development of BAT-90 platform for solid tumour cancers.
- Equity Financing Round (June 2024):
- Total: €8 million
- Participants: Led by Neva SGR S.p.A. (venture capital arm of Intesa Sanpaolo), LIFTT S.p.A., FinPosillipo (Petrone Group), Romed, and Mr. Giovanni Cerutti.
- Combined with EIC award, total secured at this point reached €18 million.
- Purpose: Grow the team and accelerate development of YntraDose® platform.
- ENEA-Tech Biomedical Foundation Investment (December 2024):
- Amount: €6 million
- Cumulative funding raised in current round by end of December reached €24 million.
- The ENEA-Tech investment came after the earlier equity round and EIC award within the same year.
Summary Table — Major Funding Events Since November 2023
| Date | Event/Source | Amount | Structure/Investors |
|---|---|---|---|
| Mar 2024 | EIC Accelerator | €10M | Grant (€2.5M) + Equity (€7.5M) |
| Jun 2024 | Equity Financing | €8M | Neva SGR, LIFTT, FinPosillipo, Romed, Giovanni Cerutti |
| Dec 2024 | ENEA-Tech Biomedical Foundation | €6M | ENEA-Tech |
Total capital raised in these events:
By December 16th 2024 BetaGlue had secured a combined total of €24 million from grant/equity awards and private investors within that calendar year.
Investor Information
The key institutional investors since late 2023 include:
- Neva SGR S.p.A. (venture capital arm of Intesa Sanpaolo)
- LIFTT S.p.A.
- FinPosillipo (part of Petrone Group)
- Romed
- Giovanni Cerutti (private investor)
- ENEA-Tech Biomedical Foundation
These were joined by participation from both new backers and existing shareholders supporting follow-on investment rounds. The European Innovation Council Fund is also a significant stakeholder via its equity component in the blended finance package.
Use of Proceeds
Funding will be deployed to:
- Advance multiple clinical programs across Europe and the United States,
- Accelerate preclinical/clinical milestones for platforms BAT‑90™ & YntraDose®,
- Expand team capabilities,
- Broaden product pipeline addressing various solid tumour indications.
Company Valuations & Exit Events
As per publicly available information up to May 2025:
Valuation:
No explicit valuation figures have been disclosed by BetaGlue Technologies or their lead investors during these rounds.Exit Events:
There are no reported exit events such as IPOs or acquisitions/buyouts involving BetaGlue Technologies since it received its EIC Accelerator funding through May 6th 2025.Sources
BetaGlue® Secures €10m EIC Accelerator Award BetaGlue® Adds €8m Equity Financing to EIC Accelerator Award ENEA-Tech Biomedical Foundation invests €6m in BetaGlue Therapeutics brings funding round total to €24m Press Release: BetaGlue Secures €10m EIC Accelerator Award3 The Press Releases
BetaGlue Therapeutics: Post-EIC Accelerator Funding DevelopmentsSince securing EIC Accelerator funding in late 2023, BetaGlue Technologies S.p.A. (rebranded as BetaGlue Therapeutics) has advanced its radiotherapy platform and financial positioning:
- Rebranding & Product Renaming: In April 2024, the company introduced a new identity as BetaGlue Therapeutics alongside its proprietary YntraDose® platform, previously known as BAT-90. The renamed YntraDose comprises four components: YntraDose-90 (radioactive microspheres), YntraDose-Guide (dosimetry software), YntraDose-Glue (biocompatible hydrogel), and YntraDose-Deliver (administration system).
- Funding Milestones: In 2024, the company raised €24 million through a combination of an €8 million equity round, a €10 million EIC Accelerator award, and a €6 million investment from ENEA-Tech Biomedical Foundation. These funds will support clinical programs in Europe and the U.S., including trials for liver, breast, lung, and other solid tumors.
- Clinical Focus: YntraDose delivers localized beta radiation via yttrium-90 microspheres embedded in a hydrogel matrix injected directly into tumors. This approach aims to minimize damage to healthy tissues while improving efficacy over external-beam radiotherapy.
- Strategic Partnerships: Collaboration with UK-based creative agency Cohesion Labs facilitated the rebranding effort, while earlier investors like Panakès Partners and Innogest Capital have continued backing its clinical-scale-up initiatives.
Sources
BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®
BetaGlue - LIFTT
ENEA-Tech Biomedical Foundation invests €6m in BetaGlue®
BetaGlue has closed a 10 million euro equity financing round
BetaGlue Technologies: closing of a EUR 10 million financing round
4 The Technology Advancements
BetaGlue Therapeutics: Post-EIC Accelerator Funding AdvancementsBetaGlue Technologies S.p.A. (rebranded to BetaGlue Therapeutics in April 2024) has made significant strides since securing a €10m EIC Accelerator Award in March 2024, following its November 2023 application. The company focuses on advancing its YntraDose® platform, a precision radiotherapy system for solid tumors, with notable progress in clinical development, commercialization, and intellectual property.
Key Advancements
- Rebranding and Platform Refinement: In April 2024, the company introduced a new identity and renamed its flagship product from BAT-90 to YntraDose®, comprising four components:
- YntraDose-Guide (dosimetry software)
- YntraDose-Glue (biocompatible "bioglue")
- YntraDose-90 (yttrium-90 microspheres)
- YntraDose-Deliver (delivery system).
- Funding Milestones: Raised an additional €24m in 2024, including an €8m equity round and a €6m investment from ENEA-Tech Biomedical Foundation. Combined with the EIC grant/equity award, this accelerates multi-indication clinical programs in Europe and the U.S..
- Clinical Development: Ongoing trials target liver, breast, lung cancers, leveraging YntraDose’s ability to deliver localized radiation while minimizing systemic side effects. No recent trial results have been publicly disclosed post-rebranding.
Technology Enhancements & Market Readiness
The platform now emphasizes ease of use for interventional radiologists through standardized dosing and personalized treatment planning tools. Industrial scale-up efforts are underway for biopsy-compatible delivery systems tested in liver/lung procedures.Intellectual Property & Research Outputs
A patent application (WO2025068543) related to radiotherapy methods was published in April 2025, though specific claims remain undisclosed. Peer-reviewed studies prior to mid-2022 validated BAT-90’s preclinical safety/efficacy, but no new publications have been announced post-EIC funding.Sources
BetaGlue Rebrand Announcement
BetaGlue’s €24M Funding Round Summary
BetaGlue Secures EIC Accelerator Award
BetaGlue Adds €8M Equity Financing
BAT–90 Preclinical Study
Patent WO2025068543 Details
5 The Partnerships and Customers
BetaGlue Technologies S.p.A. Partnerships and Strategic Collaborations BetaGlue Technologies S.p.A., an Italian clinical-stage oncology company, has established several strategic partnerships to advance its YntraDose® radiotherapy platform for solid tumor treatment. While specific customer names remain undisclosed, the following collaborations and investor relationships have been instrumental in scaling its operations:Key Partnerships and Investors
- Cohesion Labs: Collaborated on rebranding efforts in 2024, including the launch of YntraDose® (formerly BAT-90) and a new corporate identity. This partnership enhances BetaGlue’s market positioning as a precision oncology innovator.
- Artivion: Secured an exclusive global agreement for BioGlue® supply to manufacture YntraDose®, ensuring material consistency for its radiotherapy platform. This supports industrial scale-up and regulatory compliance.
- Investor Consortium: Raised €10 million in 2022 from Fin Posillipo (Petrone Group), Kairos Partners SGR, LIFTT (Stefano Buono’s VC), Neva SGR (Intesa Sanpaolo Group), Profequycapital, Romed, Innogest Capital, and Panakès Partners. These funds accelerate clinical trials for liver/breast cancer therapies and industrial scale-up of biopsy devices.
Nature of Relationships
- Clinical Collaborations: Partnered with New Hospitals in Tbilisi (Georgia) for liver cancer trials under Prof. Malkhaz Mizandari, validating YntraDose®’s precision in minimizing off-target radiation effects.
- Technology Synergies: Actively seeking partners to combine YntraDose®’s beta radiation with immunotherapy agents like checkpoint inhibitors to amplify immune responses against tumors.
Market Positioning and Scalability
BetaGlue’s alliances position it as a leader in interventional oncology by:Sources Used:
6 The Hiring and Company Growth
BetaGlue Technologies Team Growth and Development Post-EIC Accelerator FundingBetaGlue Technologies S.p.A. (now rebranded as BetaGlue Therapeutics) has significantly accelerated its team growth and operational scaling since securing a €10 million EIC Accelerator Award in March 2024, followed by an additional €8 million equity financing round in June 2024. While the company’s exact current headcount remains unspecified, the funds have been explicitly allocated to "grow the team" and expand clinical development efforts for its radiotherapy platform, YntraDose®.
Key Hiring Developments
- Recent Strategic Hires: In October 2022, BetaGlue strengthened its leadership with four key appointments:
- Betty Polikar (Head of Clinical Operations), previously at Bambino Gesù Hospital.
- Gianluca De Danieli (Head of Clinical Development), former Novartis/AAA specialist.
- Pietro Bubba Bello (Head of Manufacturing & Operations).
- Gaia Bisaccioni (Head of Quality).
- These roles focused on advancing clinical trials for BAT-90 (now YntraDose®) in breast and liver cancers while ensuring regulatory compliance and industrial scale-up.
Growth Trajectory Post-Funding
- The combined €18 million capital injection from the EIC award and equity rounds is directly supporting:
- Expansion into multiple solid tumor indications.
- Regulatory approvals in Europe and the U.S..
- The company has transitioned from early clinical-stage testing to multi-indication pipeline development, reflecting increased hiring needs across R&D, manufacturing, and quality assurance.
Leadership & Rebranding Changes
Future Scaling Objectives
New hires are critical for achieving milestones such as:- Completing ongoing trials in breast/liver cancers.
- Industrializing production processes globally.
Sources:
- BetaGlue® Technologies Announces Rebrand
- EIC Accelerator Award Announcement
- €8 Million Equity Financing Round
7 The Media Features and Publications
BetaGlue Technologies S.p.A. Media Presence and Activities Post-EIC Accelerator Funding BetaGlue Technologies S.p.A., an Italian clinical-stage oncology company, has undergone significant developments since securing €10 million in EIC Accelerator funding (announced June 2024) and raising a total of €24 million in 2024. Below is a detailed overview of its media features, publications, and activities:Media Features
- Rebranding Announcement: In April 2024, BetaGlue rebranded to BetaGlue Therapeutics, introducing its radiotherapy platform YntraDose® (formerly BAT-90). The announcement highlighted collaborations with UK-based creative agency Cohesion Labs for visual identity and website development.
- Funding Milestones: Coverage included a €6 million investment from ENEA-Tech Biomedical Foundation (December 2024), adding to earlier raises: an €8 million equity round led by Neva SGR and LIFTT S.p.A., and the EIC Accelerator Award.
Publications Featuring BetaGlue’s Technology
Peer-reviewed studies on BetaGlue’s platform include:- Anticancer Research (2022): Demonstrated efficacy of their injectable hydrogel matrix loaded with Yttrium-90 microspheres for solid tumors.
- In Vivo (2022): Validated safety profiles of BAT-90 in preclinical models.
- GEST Symposium Poster (2023): Presented early clinical data from a first-in-human trial treating hepatocellular carcinoma.
Podcasts or Interviews
No direct podcasts or interviews featuring BetaGlue executives were identified. However, CEO Dr. Colin Story provided quotes in press releases regarding funding achievements and the rebranding’s strategic importance.Conference Participation & Events
While specific conferences are not named, the company collaborates with global Key Opinion Leaders in interventional radiology, nuclear medicine, and radiation oncology. Clinical advisory board members likely represent BetaGlue at industry events related to oncology therapies.Summary of Recent Activity Timeline (2024):
| Event | Date | Details | Source Links | |-------|------|---------|--------------| | Rebranding & YntraDose® Launch | April 30 | New visual identity announced alongside four-component radiotherapy platform | Press Release Website | | €8 Million Equity Round Closing | June 6 | Led by Neva SGR/LIFTT; funds allocated to pipeline expansion | Funding Announcement EIC Update | | ENEA-Tech Investment Closing Year Total at €24M+ Financing Round Completion December16th Total raised includes earlier rounds.|||ENEA-Tech Announcement|Sources:
announces-rebrand-introduces-yntradosetm/" class="inline-link" target="_blank" rel="noopener noreferrer">BetaGlue Rebrand Press Release
(Important note: Some source URLs above contain intentional typos due to apparent transcription errors in search results; corrected versions should use: https//betaqluLe_com/[path] or exact URLs from footnotes.)
For verified sources directly related to announcements cited here visit:
(Final note due to frequent OCR-style errors in provided URLs always cross-check against official domain betalguLe_com)*
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.